Repligen | RGEN - Loan Capital


Repligen reported $542.21M in Loan Capital for its fiscal quarter ending in December of 2025.





Loan Capital Change Date
Agilent USD 3.05B 0 Dec/2025
Align Technology USD 0 0 Dec/2024
Bio Techne USD 260M 40M Dec/2025
BioMarin Pharmaceutical USD 597.18M 513K Dec/2025
Bristol-Myers Squibb USD 42.85B 1.62B Dec/2025
Bruker USD 1.85B 131.7M Dec/2025
Charles River Laboratories USD 2.14B 49.09M Dec/2025
Danaher USD 18.42B 1.58B Dec/2025
Dentsply International USD 2.02B 201M Sep/2025
Exact Sciences USD 2.33B 9.34M Sep/2025
General Electric Aerospace USD 18.81B 37M Dec/2025
Henry Schein USD 2.31B 157M Dec/2025
Illumina USD 1.49B 496M Dec/2025
IQVIA Holdings USD 13.88B 1.09B Dec/2025
Mettler Toledo International USD 2.09B 58.01M Dec/2025
Myriad Genetics USD 119.5M 60.2M Sep/2025
OraSure Technologies USD 0 0 Sep/2024
Pacific Biosciences Of California USD 893.14M 300K Sep/2024
Pfizer USD 57.41B 93M Sep/2025
Repligen USD 542.21M 4.29M Dec/2025
Revvity USD 2.63B 543K Dec/2025
Standard Biotools USD 299K 0 Sep/2025
Thermo Fisher Scientific USD 35.85B 4B Dec/2025
Waters USD 1.41B 460.24M Dec/2025
West Pharmaceutical Services USD 202.8M 100K Dec/2025